Pre-therapeutic dosimetry of normal organs and tissues of 177Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer

Purpose: 177Lu-617-prostate-specific membrane antigen (PSMA) ligand seems to be a promising tracer for radionuclide therapy of progressive prostate cancer. However, there are no published data regarding the radiation dose given to the normal tissues. The aim of the present study was to estimate the pretreatment radiation doses in patients who will undergo radiometabolic therapy using a tracer amount of 177Lu-labeled PSMA ligand. Methods: The study included seven patients with progressive prostate cancer with a mean age of 63.9 ± 3.9 years. All patients had prior PSMA positron emission tomography (PET) imaging and had intense tracer uptake at the lesions. The injected 177Lu-PSMA-617 activity ranged from 185 to 210 MBq with a mean of 192.6 ± 11.0 MBq. To evaluate bone marrow absorbed dose 2-cc blood samples were withdrawn in short variable times (3, 15, 30, 60, and 180 min and 24, 48, and 120 h) after injection. Whole-body images were obtained at 4, 24, 48, and 120 h post-injection (p.i.). The geometric mean of anterior and posterior counts was determined through region of interest (ROI) analysis. Attenuation correction was applied using PSMA PET/CT images. The OLINDA/EXM dosimetry program was used for curve fitting, residence time calculation, and absorbed dose calculations. Results: The calculated radiation-absorbed doses for each organ showed substantial variation. The highest radiation estimated doses were calculated for parotid glands and kidneys. Calculated radiation-absorbed doses per megabecquerel were 1.17 ± 0.31 mGy for parotid glands and 0.88 ± 0.40 mGy for kidneys. The radiation dose given to the bone marrow was significantly lower than those of kidney and parotid glands (p < 0.05). The calculated radiation dose to bone marrow was 0.03 ± 0.01 mGy/MBq. Conclusion: Our first results suggested that 177Lu-PSMA-617 therapy seems to be a safe method. The dose-limiting organ seems to be the parotid glands rather than kidneys and bone marrow. The lesion radiation doses are within acceptable ranges; however, there is a substantial individual variance so patient dosimetry seems to be mandatory. © 2015, Springer-Verlag Berlin Heidelberg.

Dergi Adı European Journal of Nuclear Medicine and Molecular Imaging
Cild 42
Dergi Sayısı 13
Sayfalar 1976 - 1983
Yayın Tarihi 2015
Eser Adı
[dc.title]
Pre-therapeutic dosimetry of normal organs and tissues of 177Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer
Yazar
[dc.contributor.author]
Kabasakal, L.
Yazar
[dc.contributor.author]
AbuQbeitah, M.
Yazar
[dc.contributor.author]
Aygün, A.
Yazar
[dc.contributor.author]
Yeyin, N.
Yazar
[dc.contributor.author]
Ocak, M.
Yazar
[dc.contributor.author]
Demirci, E.
Yazar
[dc.contributor.author]
Toklu, T.
Yayıncı
[dc.publisher]
Springer Berlin
Yayın Türü
[dc.type]
article
Özet
[dc.description.abstract]
Purpose: 177Lu-617-prostate-specific membrane antigen (PSMA) ligand seems to be a promising tracer for radionuclide therapy of progressive prostate cancer. However, there are no published data regarding the radiation dose given to the normal tissues. The aim of the present study was to estimate the pretreatment radiation doses in patients who will undergo radiometabolic therapy using a tracer amount of 177Lu-labeled PSMA ligand. Methods: The study included seven patients with progressive prostate cancer with a mean age of 63.9 ± 3.9 years. All patients had prior PSMA positron emission tomography (PET) imaging and had intense tracer uptake at the lesions. The injected 177Lu-PSMA-617 activity ranged from 185 to 210 MBq with a mean of 192.6 ± 11.0 MBq. To evaluate bone marrow absorbed dose 2-cc blood samples were withdrawn in short variable times (3, 15, 30, 60, and 180 min and 24, 48, and 120 h) after injection. Whole-body images were obtained at 4, 24, 48, and 120 h post-injection (p.i.). The geometric mean of anterior and posterior counts was determined through region of interest (ROI) analysis. Attenuation correction was applied using PSMA PET/CT images. The OLINDA/EXM dosimetry program was used for curve fitting, residence time calculation, and absorbed dose calculations. Results: The calculated radiation-absorbed doses for each organ showed substantial variation. The highest radiation estimated doses were calculated for parotid glands and kidneys. Calculated radiation-absorbed doses per megabecquerel were 1.17 ± 0.31 mGy for parotid glands and 0.88 ± 0.40 mGy for kidneys. The radiation dose given to the bone marrow was significantly lower than those of kidney and parotid glands (p < 0.05). The calculated radiation dose to bone marrow was 0.03 ± 0.01 mGy/MBq. Conclusion: Our first results suggested that 177Lu-PSMA-617 therapy seems to be a safe method. The dose-limiting organ seems to be the parotid glands rather than kidneys and bone marrow. The lesion radiation doses are within acceptable ranges; however, there is a substantial individual variance so patient dosimetry seems to be mandatory. © 2015, Springer-Verlag Berlin Heidelberg.
Kayıt Giriş Tarihi
[dc.date.accessioned]
2020-03-18
Yayın Tarihi
[dc.date.issued]
2015
Açık Erişim Tarihi
[dc.date.available]
2020-03-18
Dil
[dc.language.iso]
eng
Konu Başlıkları
[dc.subject]
Castration resistant
Konu Başlıkları
[dc.subject]
Lu-177-PSMA
Konu Başlıkları
[dc.subject]
Prostate cancer
Konu Başlıkları
[dc.subject]
Prostate specific membrane antigen
Konu Başlıkları
[dc.subject]
PSMA
Konu Başlıkları
[dc.subject]
Radiometabolic therapy
Konu Başlıkları
[dc.subject]
Radionuclide treatment
Haklar
[dc.rights]
info:eu-repo/semantics/closedAccess
ISSN
[dc.identifier.issn]
16197070
Yayının ilk sayfa sayısı
[dc.identifier.startpage]
1976
Yayının son sayfa sayısı
[dc.identifier.endpage]
1983
Dergi Adı
[dc.relation.journal]
European Journal of Nuclear Medicine and Molecular Imaging
Dergi Sayısı
[dc.identifier.issue]
13
Cild
[dc.identifier.volume]
42
Tek Biçim Adres
[dc.identifier.uri]
https://hdl.handle.net/20.500.11831/3055
Pubmed Id
[dc.identifier.pubmed]
PubMed ID: 26227531
Görüntülenme Sayısı ( Şehir )
Görüntülenme Sayısı ( Ülke )
Görüntülenme Sayısı ( Zaman Dağılımı )
Görüntülenme
127
20.03.2023 tarihinden bu yana
İndirme
1
20.03.2023 tarihinden bu yana
Son Erişim Tarihi
03 Ekim 2023 00:33
Google Kontrol
Tıklayınız
radiation marrow parotid glands patients kidneys calculated tracer therapy substantial radiation-absorbed ligand absorbed progressive prostate cancer images dosimetry 177Lu-PSMA-617 highest estimated showed variation Purpose Results applied through region interest analysis Attenuation correction PET/CT calculations OLINDA/EXM
6698 sayılı Kişisel Verilerin Korunması Kanunu kapsamında yükümlülüklerimiz ve çerez politikamız hakkında bilgi sahibi olmak için alttaki bağlantıyı kullanabilirsiniz.

creativecommons
Bu site altında yer alan tüm kaynaklar Creative Commons Alıntı-GayriTicari-Türetilemez 4.0 Uluslararası Lisansı ile lisanslanmıştır.
Platforms